Provenge: survival benefit did not remove commercial constraints
Original research published

Clinical value, realized revenue and a durable enterprise require separate evidence. Clarus Review examines the historical Provenge and Dendreon record: a survival result in the defined IMPACT trial population, subsequent company-level financial disclosures and the 2014 Chapter 11 filings. These observations do not provide a complete causal explanation of the corporate outcome or diminish the documented clinical result.
The article uses that distinction to challenge market estimates built from disease counts alone. A patient-specific therapy also needs clinical suitability, referral, collection, manufacturing capacity, scheduling, reimbursement, initiation and completion. Each step needs a denominator and an explanation for attrition.
For leadership teams, the practical review joins completed pathways, capacity utilization, cash collection and downside runway with clinical evidence and clinician interest. Revenue growth does not necessarily fund the installed operating base or financing obligations. This summary presents a historical operating lesson, not current product advice, a forecast, or an attribution of bankruptcy to a single cause.
Read the full Clarus Biotech Review article

